TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03208179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphadoxine-pyrimethamine
Description: Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine plus azithromycin
Description: Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
Study: NCT06564727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uniportal VATS approach
Description: Uniportal VATS resection for simple pulmonary aspergilloma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS approach
Description: VATS resection for complex pulmonary aspergilloma
Study: NCT03491306

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breflex
Description: In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality.
Study: NCT04396665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precam
Description: 6 months Web-App intervention related with: diet, physical activity, self-care and breast cacner risk prevention
Study: NCT00691067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: 200 mg po per day x 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study: NCT02099539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
Study: NCT02297243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinopsys Lacrimal Stent
Description: The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
Study: NCT03668769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Mobile Technology
Description: Use Quitting Schedule mobile smartphone app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study: NCT02099539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
Study: NCT02911571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMprofiler SKY92 gene signature
Description: MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis
Study: NCT02749331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdVince
Description: Virus solution for infusion in intrahepatic artery
Study: NCT02669225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]florbetaben
Description: PET radiotracer to image Amyloid beta (AB) load in human brain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]florbetaben
Description: PET radiotracer to image Amyloid beta (AB) load in human brain.
Study: NCT03668769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Participate in individual smoking cessation program
Study: NCT03707054

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Study Arm
Description: Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
Study: NCT04865640

Intervention type: DIAGNOSTIC_TEST
Intervention: Noninterventional and noninvasive
Description: The ADI At-Home CPM (Cardiopulmonary Management) System is intended for adults undergoing monitoring for cardiopulmonary conditions under the direction of a licensed medical professional to measure, record, and periodically transmit physiological data.
Study: NCT00382096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin + Metformin
Study: NCT00722553

Intervention type: DRUG
Group type: OTHER
Intervention: Pralatrexate Injection
Description: Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.
Study: NCT03712631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunneling technique bone augmentation
Description: horizontal ridge augmentation using mixture of xenograft,autogenous bone
Study: NCT00722553

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin B12
Description: 1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.
Study: NCT03712631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tunneling technique bone augmentation
Description: horizontal ridge augmentation using mixture of xenograft,autogenous bone
Study: NCT02155569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraperitoneal Cesarean
Description: Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal Cesarean
Description: Pfannenstiel-Kerr technique for laparatomy and uterine entry
Study: NCT01243671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study: NCT01225887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Given PO
Study: NCT02869438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
Study: NCT05154201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIN1001
Description: Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
Study: NCT01840618

Intervention type: DEVICE
Intervention: Nasal Continuous positive airway pressure (CPAP)
Description: We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.

Intervention type: DEVICE
Intervention: Nasal Continuous positive airway pressure (CPAP)
Description: We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
Study: NCT00903318

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire about family's characteristics taking about 30-35 minutes to complete.
Study: NCT00890266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking with hypotonic riboflavin
Description: Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
Study: NCT02977130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Map group
Description: diabetes shared care plus conversation map intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: diabetes shared care
Study: NCT03711201

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group IORE
Description: This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
Study: NCT00749515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HIDA
Description: All patients had a HIDA scan to assess physiologic liver clearance capacity.
Study: NCT04058418

Intervention type: OTHER
Intervention: Survey Administration
Description: Completion of a short survey.
Study: NCT02080858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + Apixaban + ASA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor + Apixaban
Study: NCT03642665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural cycle
Description: no medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate
Description: Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone
Description: Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
Study: NCT01284582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATH03
Description: 4 vaccinations
Study: NCT03829488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
Description: Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% SODIUM CHLORIDE 9g/L injection BP
Description: Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
Study: NCT01284582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATH03
Description: 4 vaccinations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATH03
Description: 4 vaccinations
Study: NCT00722553

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic Acid
Description: 1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate.
Study: NCT03816982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-injection bupivacaine HCl plus liposomal bupivacaine
Description: Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB
Description: Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
Study: NCT01606644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Description: Inhalation of 100% oxygen for 90 minutes
Study: NCT03148418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered as directed per the parent study.
Study: NCT02188225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 10 mg/ daily
Study: NCT00591344

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training
Description: Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Fitness Counts
Description: The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
Study: NCT01480765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
Study: NCT00694707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules
Study: NCT01480765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: 150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine infusion
Description: 0.1mg/kg/hr for 48 hours post operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Normal saline placebo intravenous infusion for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo infusion
Description: Normal saline placebo intravenous infusion for 48 hours
Study: NCT04668599

Intervention type: OTHER
Intervention: Cardiopulmonary rehabilitation
Description: Patients will undergo standardized cardio-pulmonary rehabilitation program.
Study: NCT04456673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT00694707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules
Study: NCT04438603

Intervention type: DRUG
Intervention: Intervention for incipient patients at low risk of disease progression
Description: Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
Study: NCT00694707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Risperidone was supplied in capsules
Study: NCT02640716

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multi-domain internet-based adaptive training program
Description: The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
Study: NCT04456673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Corticosteroid
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Corticosteroid
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Long-Acting Beta Agonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Long-Acting Beta Agonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Long-Acting Muscarinic Antagonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Long-Acting Muscarinic Antagonist
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous